GlassScriptPhysician profile
Bryan P Pucik
NPI 1073592077
$588.02
in general payments reported to CMS, 2019-2025
28 companies · $74.87 in 2025
The $74.87 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.56 · 2020: $35.53 · 2021: $55.45 · 2022: $106 · 2023: $95.18 · 2024: $127 · 2025: $74.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $52.00 | 2022-2023 | Injectafer |
| Radius Health, INC. | $47.53 | 2024 | Tymlos |
| Philips North America LLC | $33.32 | 2019-2020 | |
| Exact Sciences Corporation | $31.86 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $31.72 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $31.65 | 2022-2024 | Krystexxa |
| Janssen Pharmaceuticals, INC | $29.19 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.87 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $23.60 | 2019-2020 | |
| Abbott Laboratories | $23.06 | 2022 | |
| Melinta Therapeutics, LLC | $23.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.78 | 2024 | Trintellix |
| Electromed, INC. | $16.67 | 2024 | Smartvest |
| Pfizer INC. | $16.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.92 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.07 | 2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $13.99 | 2024 | Voquezna |
| Kyowa Kirin, INC. | $13.58 | 2023 | Crysvita |
| Lilly USA, LLC | $13.57 | 2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $13.51 | 2023 | Eliquis |
| Vanda Pharmaceuticals INC. | $13.16 | 2019 | |
| Therapeuticsmd, INC. | $13.04 | 2019 | |
| Astellas Pharma US INC | $12.72 | 2022 | |
| Corium, LLC | $12.68 | 2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $12.66 | 2020 | |
| Abbvie INC. | $12.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.66 | 2021 | |
| Sobi, INC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Pucik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.